Current etf page

ETF Analytics

XBI ETF Holdings & Fundamentals

Fund Profile · Cost · Size · Liquidity · Exposure

Financial ServicesAsset ManagementScore data as of Oct 30, 2026

XBIState Street SPDR S&P Biotech ETF

Financial Services / Asset Management

Low Priority

Above Peers

NeutralEdge 7/10
$155.98−$1.81 (−1.15%)

Latest quote

  • Momentum
    70
  • Value
    48
  • Quality
    65
  • Risk resilience
    56
  • Sentiment
    —
algovestiq.comScore data as of Oct 30, 2026

XBI Holdings

156 holdings; the ten largest make up 15.94% of the fund. Holdings as of Sep 12, 2026.

Holdings
156
Top 10 weight
15.94%
Share of the fund in its ten largest positions
Largest holding
MRNA
2.87%
Expense ratio
0.35%
$35.00 a year per $10,000
Fund size
$8.16B
Top 25 holdings by weight
RankSymbolHoldingWeightMarket value
1MRNAMODERNA INC2.87%$303.43M
2TWSTTWIST BIOSCIENCE CORP1.81%$191.2M
3HALOHALOZYME THERAPEUTICS INC1.47%$155.02M
4NTRANATERA INC1.46%$153.9M
5KYMRKYMERA THERAPEUTICS INC1.45%$152.77M
6TVTXTRAVERE THERAPEUTICS INC1.40%$147.54M
7ROIVROIVANT SCIENCES LTD1.39%$147.2M
8ORKAORUKA THERAPEUTICS INC1.38%$146.21M
9RVMDREVOLUTION MEDICINES INC1.36%$144.06M
10PRAXPRAXIS PRECISION MEDICINES I1.36%$143.69M
11INSMINSMED INC1.34%$141.5M
12PTGXPROTAGONIST THERAPEUTICS INC1.33%$140.18M
13DNTHDIANTHUS THERAPEUTICS INC1.31%$138.04M
14REGNREGENERON PHARMACEUTICALS1.27%$134.7M
15CGONCG ONCOLOGY INC1.27%$133.91M
16PCVXVAXCYTE INC1.25%$132.46M
17SMMTSUMMIT THERAPEUTICS INC1.23%$129.98M
18SRRKSCHOLAR ROCK HOLDING CORP1.22%$128.97M
19ERASERASCA INC1.16%$122.47M
20RLAYRELAY THERAPEUTICS INC1.16%$122.17M
21RYTMRHYTHM PHARMACEUTICALS INC1.15%$121.79M
22GILDGILEAD SCIENCES INC1.15%$121.75M
23IOVAIOVANCE BIOTHERAPEUTICS INC1.15%$121.35M
24TGTXTG THERAPEUTICS INC1.15%$121.36M
25VRTXVERTEX PHARMACEUTICALS INC1.14%$120.63M

XBI Expense Ratio

XBI charges 0.35% a year, about $35.00 for every $10,000 invested.

Yearly cost by amount invested
InvestedCost a year
$10,000$35.00
$25,000$87.50
$100,000$350.00

The fee is taken from the fund's assets rather than billed, so it shows up as slightly lower returns.

ETF Analytics Snapshot

Current ETF evidence uses fund profile, cost, size, distribution, momentum, and risk fields.

Price
$155.98
As of Oct 30, 2026
Fund size
$8.16B
Expense ratio
0.35%
Distribution yield
0.35%
SPDR ETF evidence

ETF pages use fund-native profile fields for cost, size, liquidity, holdings breadth, NAV, issuer, and launch date.

Review ETF analytics
Holdings
156
NAV
$157.82
Average volume
9M
Inception
Jan 31, 2006
Asset class
Equity
Primary exposure
Healthcare (99.28%)
Beta
1.1
Momentum score
70/100

ETF Fundamentals Overview

Fund-native evidence replaces stock-only quarterly statement fields for ETF pages.

Fund profile

FieldValue
Fund nameState Street SPDR S&P Biotech ETF
IssuerSPDR
Asset classEquity
Primary exposureHealthcare (99.28%)
DomicileUS
Inception dateJan 31, 2006
Websitehttps://www.ssga.com/us/en/institutional/etfs/state-street-spdr-sp-biotech-etf-xbi

Current ETF metrics

FieldValue
Fund size$8.16B
Expense ratio0.35%
Holdings count156
NAV$157.82
Average volume9M
Distribution yield0.35%
Beta1.1

ETF Exposure

Sector and country weights of the fund's holdings.

Sector exposure
FieldValue
Financial Services0.72%
Healthcare99.28%
Country exposure
FieldValue
Ireland0.08%
Switzerland1.43%
United States96.65%
China0.05%
Netherlands0.50%
United Kingdom1.29%

ETF Risk-Adjusted Context

Risk and return-efficiency metrics sit beside fund structure rather than company financial statements.

AIQ Score
60/100

Composite research read.

Sharpe Ratio
1.23

Return per unit of total volatility.

Sortino Ratio
—

Return per unit of downside volatility.

Max Drawdown
-14.88%

Largest trailing drawdown in the risk window.

Momentum
70/100

Trend and price behavior.

Value Exposure
48/100

Relative valuation/exposure context.

Risk
56/100

Volatility and downside resilience.

Annual Volatility
29.06%

Annualized realized volatility.

ETF analytics context
How to read XBI's ETF profile

Read cost, fund size, liquidity, holdings breadth, NAV, distribution yield, and exposure together. ETF analytics should not be judged by company-only fields such as revenue, EPS, margins, or payout ratio when those rows are not applicable.

Analysis tools

Export and portfolio tools complement the ETF evidence above.

Fundamentals export

Current evidence CSV · Pro workflow

Unlock with Pro
Portfolio context

Holding, weight, concentration · Personalized to holdings

Unlock with Premium
Continue to XBI AIQ Pro
See how ETF evidence contributes to the full analysis workspace.

How to Read a Fundamental Profile

Fundamental analysis is the discipline of estimating what a business is worth by examining the financial evidence it produces: how much it earns, how efficiently it converts revenue to cash, how much capital it uses to produce those earnings, and whether the current price compensates an investor for the risks of holding it. The metrics on this page are organized into six evidence buckets -- valuation, profitability, leverage, growth, efficiency, and company size -- because each bucket answers a different question. Valuation multiples answer whether the market price is cheap or expensive relative to underlying earnings power. Profitability answers whether the business model is inherently strong or thin. Leverage answers whether the balance sheet is durable under stress. No single ratio tells a complete story; the analysis is about how the full set hangs together.

The single most diagnostic question in fundamental analysis is whether a business generates returns on invested capital above its cost of capital. A business that earns 20% ROIC while its cost of capital is 9% is compounding value for shareholders at an 11-point spread -- and the market will typically pay a meaningful premium to book value for that privilege. A business that earns 8% ROIC against a 10% cost of capital is destroying economic value even if reported earnings are growing, because growth at below-cost returns dilutes per-share value rather than building it. This is why ROIC and gross margin -- which measures the inherent advantage in the product before overhead -- are the highest-signal fundamental metrics for evaluating business quality at the model level.

Valuation multiples (P/E, EV/EBITDA, P/S, P/FCF) measure what the market currently demands per unit of earnings, sales, or cash flow. They are not independently actionable: a low P/E can indicate value or distress, and a high P/E can indicate genuine quality or speculative excess. The interpretive work is contextual -- comparing a multiple to sector peers, to the company's own history, and to the underlying growth rate. The PEG ratio (P/E divided by earnings growth rate) is a simple first-order adjustment; EV/EBITDA is more reliable for cross-capital-structure comparisons because it normalizes for debt. FCF yield (FCF / market cap) is the cleanest single valuation signal for mature businesses because it is harder to manipulate than GAAP earnings.

Growth metrics deserve careful handling. Revenue growth that outpaces earnings growth signals margin compression -- revenue expansion without profitability improvement. EPS growth that outpaces revenue growth often reflects share buybacks rather than operational leverage, which is worth distinguishing. The highest-quality growth signature is expanding ROIC alongside revenue growth: the business is finding new markets without sacrificing the economics that made the existing business attractive. Declining ROIC with accelerating revenue growth is the opposite -- scale without economics, often the precursor to a valuation reset.

How to Read This Table

  • Valuation multiples (P/E, EV/EBITDA): Compare within sector and against the company's own 5-year history before concluding cheap or expensive.
  • ROIC vs WACC spread: The most important single quality signal. Sustained ROIC above cost of capital is the foundation of durable long-term returns.
  • Gross margin: Measures inherent product economics before overhead. Declining gross margin at scale is an early warning sign.
  • Debt-to-Equity and Interest Coverage: Frame balance sheet durability. Interest coverage below 3x reduces resilience in stress.
  • FCF yield: Divide trailing free cash flow by market cap. Yields above 4-5% are generally constructive; negative FCF yield requires a clear path to conversion.
  • Revenue growth vs. EPS growth: The gap between them tells you whether scale is creating or consuming margin.

These are analytical tools, not investment recommendations. Historical patterns do not guarantee future results.

XBI ETF Analytics FAQ

What is XBI's expense ratio?

XBI's expense ratio shows the annual fund cost when available. Compare it with holdings, tracking exposure, liquidity, dividend yield, and volatility.

What is XBI's dividend yield?

XBI's dividend or distribution yield helps investors compare income potential. It should be weighed against fund strategy, expense ratio, and risk.

How diversified is XBI?

XBI's diversification depends on holdings count, top-position concentration, and sector exposure. Fund size and liquidity do not automatically mean broad diversification.

Is XBI overvalued or undervalued?

ETF valuation depends on the valuation of its underlying holdings, sector exposure, and market regime. Use fund fundamentals with risk and technical context.